The Latest Breaking News from Cardinal Health

Jason Hollar, the Gen X boss of the $38 billion Fortune 500 healthcare giant, overhauled the business—and he says employees were also over being "frustrated that we weren't succeeding."

These three dividend companies all share one common trait: strong earnings growth and rising cash flow.

These three dividend companies all share one commonality: near-perfect buy ratings and breakout potential.

These buy-rated Dividend Aristocrats are trading at rare discounts, offering strong yields, bullish ratings, and potential long-term upside.

Discover 3 Dividend Aristocrats with high earnings growth, low payout ratios, and strong analyst ratings: perfect for long-term income investors.

While the market has rallied off its April lows, uncertainty continues to dominate investor sentiment. To avoid the volatility, consider these three stocks.

These three dividend stocks easily beat the S&P 500's return in 2025 while offering predictable earnings and dividend growth.

Cardinal Health has delivered robust gains over the past year, outperforming the broader market, and analysts are highly bullish on its outlook.

Cardinal Health (CAH) rallied to a new record high on Thursday and closed the day 3% higher. Cardinal Health rallied after its release of positive fiscal Q3 earnings results and a hike in guidance for the full year. The company remains in a long-term 3-year uptrend. Company Description: Cardinal Health...

Cardinal Health is scheduled to announce its third-quarter results next month, with analysts anticipating a single-digit earnings growth.

Summary Cardinal Health (CAH) shows strong technical buy signals, with a 3.95% gain since the Trend Seeker buy signal on 3/18 and consistent price appreciation. The company operates globally, providing a wide range of healthcare services and products, including pharmaceuticals, medical supplies, and radiopharmaceuticals. Barchart's technical indicators highlight CAH's positive...